🇺🇸 FDA
Patent

US 12319744

Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 12319744 (Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)) held by The Board of Regents of the University of Texas System expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K38/4846, A61K9/0019